Guest guest Posted February 27, 2010 Report Share Posted February 27, 2010 1. Heartwire Increased Risk of Diabetes Observed Among Statin-Treated Patients 2/17/10 — New data from a large meta -analysis of major statin trials suggests the LDL-cholesterol–lowering drugs slightly increase the risk of developing diabetes mellitus. Investigators stress, however, that clinical practice should remain unchanged in patients with moderate or high cardiovascular risk, given the low absolute risk of developing diabetes, particularly when when compared with the benefit of statins. " We found that there was indeed a risk of DMabout 9%, but it isn't a worrying increase as had been suggested by other studies, " said co–lead investigator.Dr Nissen praised the researchers and agreed with their conclusions, stating that the benefits of statins exceed the risk of diabetes and that physicians should not alter clinical practice based on these findings. . " Whatever this effect is, it doesn't lessen the favorable effect of statins on clinical outcomes. I don't think people should hesitate to give prediabetic patients statins because they might develop diabetes a few weeks or a few months later and deny them all the other benefits of these drugs. " 2.%% Medscape Diabetes & Endocrinology - Re-thinking the Diagnosis of Diabetes: Is A1C the Final Answer? 2/9/10 In July 2009, an international expert committee published a report that made the case for using the hemoglobin A1C assay to diagnose T2DM. The committee included members appointed by (ADA), European Assoc for the Study of Diabetes (EASD), and the Internat Diabetes Fed (IDF). Summary, the expert panel has suggested that the A1C assay be used to diagnose DM recommending 6.5% as the diagnostic threshold, and the ADA has now accepted the suggestion. .in 2008, another group suggested the very same thing. If an expert panel wanted to take on the topic of diagnosing DM, perhaps it is time to turn away from the glucose-centric definition to one that more clearly represents the full cardiometabolic risk of the individual patient. 3.%% MW Monitoring Helps Stop Drug-Associated Hyperkalemia Events in Diabetics ) Feb 10 - Angiotensin-converting enzyme inhibitors and other agents that block the renin-angiotensin -aldosterone (RAA) system are used to slow the progression of renal disease in patients with T2 and hypertension. However, these drugs can cause hyperkalemia. [high potassium] [27355 patients] Overall, subjects with potassium monitoring were 50% less likely to have a hyperkalemia event. For patients with chronic kidney disease, the risk reduction with monitoring was -- 71%. " This study offers tangible evidence to support published guidelines that recommend monitoring serum potassium among patients with these clinical characteristics who are started on RAA system inhibitors, " the authors conclude. J Gen Intern Med 2010. 4.%% Exercise and Type 2 Diabetes 2/09/2010 Retinopathy. Although exercise increases systemic and retinal blood pressures, there is no evidence that physical activity acutely worsens the retinopathy present in DM. Bernbaum et al found that T1 & T2 individuals with proliferative retinopathy who engaged in a low -intensity training program improved cardiovascular function by 15%. Thus, in a well- supervised environment, low-intensity aerobic activity can be safely performed by persons with retinopathy. they need to be cautioned about engaging in activities that cause blood pressure to increase dramatically, such as head-down or jarring activities or those with arms overhead... Physical activity affords significant benefits for those with T2. . Several factors including muscle fiber composition, low capillary density, obesity, and older age require that physical activity be initiated at lower intensity/ duration and be increased gradually to reduce risks and contribute to maintenance of physical activity by those with T2.. 5.%% Tailoring Treatment to the Individual in T2DM 2/11/10; Int J Clin Pract. 2010;64(3): Abstract - Good glycaemic control continues to be the most effective therapeutic manoeuvre to reduce the risk of development and/or progression of microvascular disease, and therefore remains the cornerstone of DM management.. Our recently updated '10 steps to get more T2 patients to goal' remains the blueprint in terms of practical guidance for helping patients to achieve and maintain their glycaemic targets. However, having reviewed the evidence, we recognise that individualising targets and/or treatment according to patient type is paramount. For example, while early intervention is preferred wherever appropriate, certain high risk groups may not respond to overly intensive glucose- lowering regimens. Table 1. Individualising the '10 steps to get more T2 diabetes patients to goal' according to patient type.. 6.%% Classification System for Diabetic Nephropathy May Advance Patient Care 2/18/10 An international group of physicians has designed a categorization system for diabetic nephropathy (DN), the chief cause of kidney failure. " DN is a complex condition with varying degrees of severity and varying effects on the kidneys, " write the researchers. The team separated DN into 4 classes, based on biopsy findings. They range from the least severe (class 1) to the most severe (class 4): ..The classification system will help scientists discover more about the pathways of DN progression, and therefore improve patient care, the authors predict. They note future research should focus on evaluating clinical results. 7.%% MW Diabetes Drug Stinks, Doctors Find (Reuters) Feb 16 - Metformin stinks, literally, and this may explain why many patients stop taking it a group of doctors wrote.. It smells like fish or dirty socks to some people, and this could account for the well known side effects of the drug, which can make people nauseated. But the problem could be solved by coating the pills so they do not smell or release the odor into the stomach, where it can be burped up. One patient had taken brand-name metformin (Glucophage) before being switched to an immediate- release, generic version which he refused to take. An extended release generic version, coated to make it dissolve more slowly, solved the problem. . " Trial of a film-coated, extended-release formulation may be a reasonable approach in such cases. " 8.%% Dolphins have diabetes off switch BBC News 2/19/10 A study in dolphins has revealed genetic clues that could help medical researchers to treat T2DM. Scientists said that bottlenose dolphins are resistant to insulin - just like people with DM. But in dolphins, this resistance is switched on and off. insulin - the hormone that reduces the level of glucose in the blood - has no effect on the dolphins when they fast. In the morning, when they have their breakfast, they simply switch back into a non-fasting state. . the mammals may have evolved this fasting-feeding switch to cope with a high-protein, low-carbohydrate diet of fish. " Bottlenose dolphins have large brains that need sugar, Since their diet is very low in sugar, " it works to their advantage to have a condition that keeps blood sugar in the body… to keep the brain well fed " . . other marine mammals, such as seals, do not have this switch, and they think that the " big brain factor " could be what connects human and dolphin blood chemistry. “And we have found changes in dolphins that suggest that [this insulin resistance] could get pushed into a disease state. " If we started feeding dolphins Twinkies, they would have diabetes. " They hope to work with medical researchers to turn the discovery in dolphins into an eventual treatment for humans. 9.%% NYTimes 2/20/10 Research Ties Diabetes Drug to Heart Woes Hundreds of people taking Avandia, a controversial DM drug needlessly suffer heart attacks and heart failure each month, according to confidential government reports that recommend the drug be removed from the market. ..MedWatch 2/23/10 FDA Safety Information and Adverse Event Reporting Program - Avandia (rosiglitazone): FDA notified healthcare professional and patients that it is reviewing the primary data from a large, long-term clinical study, RECORD, on possible cardiovascular [CV] risks with Avandia. In addition to the clinical trial, a number of observational studies of the CV safety of rosiglitazone have been published and FDA has been reviewing these on an ongoing basis. . no new conclusions or recommendations about the use of [Avandia] in the treatment of T2DM have been made at this time. .the agency will present the totality of new and existing CV safety data on Avandia in July 2010. FDA recommends that healthcare professionals follow the recommendations in the drug label. Patients should continue taking rosiglitazone unless told by their healthcare professional to stop. Patients who are concerned about the possible risks associated with using rosiglitazone should talk to their healthcare professional. 10.%% Diabetic Retinopathy and Blockade of the Renin–Angiotensin System: New Data from the DIRECT Study Programme 2/17/10; Eye. 2010;24(1): %%In summary, we suggest that candesartan should be considered for all 'at risk patients' with T1DM those of more than 6-year duration of diabetes, especially if there is an indication for RAS blockade such as the presence of albuminuria or hypertension. In T2DM, candesartan should be considered for patients with early stages of diabetic retinopathy, particularly if there is an indication for RAS blockade. Key points - Vascular risk factors must be addressed Blood glucose, BP control, & lipid lowering are important * Caution and counselling in women of child-bearing age, and this drug should be discontinued if planning for pregnancy or on the first notification of pregnancy. 11.%% MW Diabetes Slows Return of Continence After Laparoscopic Prostatectomy 2/12/10— Patients with DM who undergo laparoscopic radical prostatectomy often experience a slower return of urinary continence than do men without DM. study found that 43.7% of DM patients are continent within 3 months of surgery vs 57.8% of non-diabetics. .The findings also suggest that diabetics who've had DM for 5 years or longer are nearly 5 times more likely to have post- prostatectomy incontinence than are those with a shorter disease duration. In addition, an elevated HbA1c value was predictive of incontinence on long-term follow-up. " Urinary incontinence remains a clinically important complication after radicalprostatectomy and has a significant negative impact on patient quality of life, " said the senior author [135 diabetics/ 135 controls.] J Urol.2010;:Reuters Health 12.%% Diabetes Feb 2010 vol. 59 no. 2 Duration of Lactation and Incidence of the Metabolic Syndrome in Women of Reproductive Age According to Gestational Diabetes Mellitus *GDM) Status: A 20-Year Prospective Study in CARDIA (Coronary Artery Risk Development in Young Adults) [1399 women 39% black age 18–30 years) Conclusions Longer duration of lactation was associated with lower incidence of the metabolic syndrome years after weaning among women with a history of GDM and without GDM, controlling for preconception measurements, BMI, and sociodemographic and lifestyle traits. Lactation may have persistent favorable effects on women's cardiometabolic health. 13.%% Nat Rev Endocrinology 6 March 2010 | Type 1 diabetes mellitus (T1DM) is a chronic condition characterized by autoimmune destruction of the pancreatic ß cells; as a consequence, affected individuals are unable to produce insulin and maintain adequate glucose homeostasis. Daily administration of exogenous insulin has long been the mainstay of the clinical management of patients with T1; however, therapeutic use of insulin has a number of drawbacks. Although efforts have been made to address at least some of these problems, novel approaches to the treatment of T1DM are clearly warranted. Over the past decade, increased understanding of the pathogenesis of T1DM, at both the molecular and cellular level, has aided the development of potential noninsulin-based therapies for T1 These therapies are diverse in nature and range from stem-cell transplantation to replenish the damaged pancreatic ß cells to modulation of the immune response. Other approaches aim to prevent development of T1DM in the first place. This Focus issue provides an expert overview of noninsulin therapies currently in development or clinical trials, all of which have been identified by leaders in the field as promising strategies for the future management of patients with T1DM. 14.%% Nature Reviews Endocrinology 6, (Mar 2010) FOCUS ON: Noninsulin therapies for T1DM :[NRE 3/2010 T1] Immunomodulation with microbial vaccines to prevent T1 Abstract - Selected bacteria, viruses, parasites and nonliving, immunologically active microbial substances prevent autoimmune DM in animal models. Such agents might also have a protective effect in humans by providing immune stimuli critical during childhood development. The 'hygiene hypothesis' proposes that reduced exposure to environmental stimuli, including microbes, underlies the rising incidence of childhood autoimmune diseases, including T1DM. This hypothesis is supported by data that highlight the importance of infant exposure to environmental microbes for appropriate development of the immune system.. This finding raises the possibility of using live, nonpathogenic microbes (for example, probiotics) or microbial components to modulate or 're-educate' the immune system and thereby vaccinate against T1. Progress has been assisted by the identification of receptors and pathways through which gut microbes influence development of the immune system. 15.%% [NRE 3/2010 T1]] :Stem cell therapy for T1DM Abstract - The use of stem cells in regenerative medicine holds great promise for the cure of many diseases, including T1 Any potential stem-cell-based cure for T1DM should address the need for ß-cell replacement, as well as control of the autoimmune response to cells which express insulin. The ex vivo generation of ß cells suitable for transplantation to reconstitute a functional ß-cell mass has used pluripotent cells from diverse sources, as well as organ-specific progenitor cells from the liver and the pancreas. The most effective protocols to date have produced cells that express insulin and have molecular characteristics that closely resemble bona fide insulin-secreting cells; however, these cells are often unresponsive to glucose This Review focuses on current strategies to obtain cells which express insulin from different progenitor sources and highlights the main pathways and genes involved, as well as the different approaches for the modulation of the immune response in patients with T1DM. 16.%% [NRE 3/2010 T1] Selective depletion of B lymphocytes with rituximab preserves ß-cell function Selective depletion of B lymphocytes could represent a novel approach to the management of patients with newly diagnosed T1 according to phase II data. “.. a treatment that specifically targets B cells can lead to preservation of insulin secretion,” explains a lead researcher.“It now opens the field up to alternative therapies that target B cells, either as single agents or perhaps combined with other agents.” The progressive autoimmune destruction of pancreatic ß cells characteristic of T1 is widely believed to involve T lymphocytes. However, studies of the nonobese diabetic (NOD) mouse suggested that B lymphocytes might also play a part. . rituximab—a chimeric anti-CD20 monoclonal antibody developed to treat hematological neoplasias -has shown promise for the treatment of autoimmune diseases, such as rheumatoid arthritis. [87 patients with newly diagnosed T1] results of this study suggest that selective depletion of B lymphocytes can preserve ß-cell function in patients with new- onset T1. The next step is to optimize therapies that target B lymphocytes. 17.%%[NRE 3/2010 T1] Immune therapy for T1DM what is unique about anti-CD3 antibodies? T1 is a prototypic organ-specific autoimmune disease that results from selective destruction of insulin-secreting ß-cells by immune-mediated inflammation (insulitis), that is, the infiltration of pancreatic islets by autoreactive CD4 + and CD8+ T lymphocytes. Current treatment is substitutive - chronic use of exogenous insulin -which, in spite of considerable advances, is still associated with constraints and lack of effectiveness over the long-term in relation to the prevention of vascular and neurological complications. Finding a cure for T1DM is an important medical health challenge, as the disease's incidence is steadily increasing in industrialized countries and projections of future prevalence are alarming. Crucially, as T1 mainly affects children and young adults, any candidate immune therapy must be safe and avoid chronic use of immunosuppressants that promote sustained depression of immune responses. The ideal approach would, therefore, involve induction or, in the case of established T1 restoration of immune tolerance to target autoantigens. This Review presents, in particular, 2 strategies that are still in clinical development but hold great promise - the use of candidate autoantigens and anti-CD3 monoclonal antibodies. Autoimmune diseases such as T1 ensue from the rupture of tolerance to self antigens, which is usually maintained through a variety of immune mechanisms.. it is well accepted that both genetic and environmental factors (with either a predisposing or a protective role) are involved...T lymphocytes involved in T1DM are heterogeneous, and include pathogenic cells (both CD4 + and CD8+ T cells) and specialized subsets of regulatory T cells (TREG) that play a key role in the control of disease progression. Recent studies also stress the role of inflammatory mediators in the amplification of the immune reaction.Various candidate autoantigens have been identified as possible triggers of T1DM, including the main ß-cell hormone insulin (or proinsulin) itself, glutamic acid decarboxylase (GAD), a ß-cell-specific protein phosphatase, a peptide of heat shock protein 60 (hsp60), IGRP (also called glucose-6-phosphatase 2), and the most recently characterized zinc transporter, ZnT8, which is a preferential target of pathogenic CD8 + T cells...Immune therapy represents the only sensible therapeutic option for T1DM, as it is the only way to tackle the causal pathogenic mechanisms. Well-designed immune intervention trials have been conducted and from the data recovered, major proofs of concept have emerged. The aim of this Review is to outline these strategies and their pros and cons. .[90pages +]© 2010 Nature Publishing Group, a division of Macmillan Publishers Limited. 18.%%[NRE 3/2010 T1]: Blockade of interleukin 1 in T1DM Abstract - Interleukin 1 (IL-1) is a 17 kDa protein highly conserved through evolution and is a key mediator of inflammation, fever and the acute-phase response. IL-1 has important functions in the innate immune defense against microbes, trauma and stress, and is also an effector molecule involved in tissue destruction and fibrosis. The inhibition of IL-1 action has clinical efficacy in many inflammatory diseases, such as hereditary auto-inflammatory disorders, gout, rheumatoid arthritis and T2DM - a common metabolic condition caused by insulin resistance and pancreatic ß-cell failure, the causes of both of which have inflammatory components. IL-1 signaling has roles in [includes] ß-cell dysfunction.. In addition, IL-1 acts on T-lymphocyte regulation. Genetic or pharmacological abrogation of IL-1 action reduces disease incidence in animal models of (T1DM) and clinical trials have been started to study the feasibility, safety and efficacy of IL-1 therapy in patients with T1 Here, we review the rationale for blocking IL-1 in patients with T1DM. 19.%% [NRE 3/2010 T1]:Stem cell and gene therapies for diabetes mellitus Abstract - In this Perspectives article, we comment on the progress in experimental stem cell and gene therapies that might one day become a clinical reality for the treatment of patients with diabetes mellitus. Research on the ability of human embryonic stem cells to differentiate into islet cells has defined the developmental stages and transcription factors involved in this process. However, the clinical applications of human embryonic stem cells are limited by ethical concerns, as well as the potential for teratoma [tumor] formation. As a consequence, alternative forms of stem cell therapies, such as induced pluripotent stem cells and bone marrow-derived mesenchymal stem cells, have become an area of intense study. Finally, gene therapy shows some promise for the generation of insulin-producing cells. Here, we discuss two of the most frequently used approaches: in vitro gene delivery into cells which are then transplanted into the recipient and direct delivery of genes in vivo. 20.%% .Excessive Weight Gain in Early Pregnancy Linked to Gestational Diabetes (GDM) 2/23/10 The lead author( Kaiser Permanente Med Group Oakland,) said " Our research shows that weight gain in early pregnancy is a modifiable risk factor for GDM. Randomized studies are needed to determine the feasibility of this early intervention and the best methods to help women meet the [institute of Medicine] recommendations. " [345 patients with GDM & 800 controls] screened for GDM at 24 -28 wks of gestation. When compared with the lowest [3rd] of rate of gestational weight gain < 0.60 lb/wk, higher rates of weight gain were associated with increased risks for GDM. The association was stronger in obese or overweight women & in nonwhite women. Obstet Gynecol 2010;115: 21.%% MW Walnuts Shown to Improve Endothelial Function in Diabetics 2/22/10 The daily consumption of walnuts has the potential to improve endothelium function and plasma lipids in patients with T2DM With a high polyunsaturated and monounsaturated fat content, many types of nuts have gained favor as a healthy addition to any diet, and walnuts, in particular, have a high level of omega-3 fatty acids. Researchers theorized that the addition of walnuts could provide cardiovascular [CV] benefits to diabetics. " We know nuts are rich in fiber, and have a variety of micronutrients, minerals, B vitamins, magnesium, and a number of properties that make them a likely candidate for benefits in people with CV risk, " a coauthor said. [randomized controlled crossover trial - 24 T2 subjects]The primary outcome measure for the study was a change in flow-mediated dilatation (FMD) after 8 weeks, and secondary outcome measures included changes in plasma lipids, (HbA1c), fasting glucose, insulin sensitivity. There was a significant improvement in FMD among the participants consuming the walnut-enriched diet, compared with those not consuming diets with walnuts " We did not see significant improvement compared with placebo in a variety of the other cardiac risk factors we measured as secondary outcomes, but when it comes to endothelial function, I'm reminded of The Lord of the Rings. It's the 1 ring to rule them all, " he said. " What it tells us is how the blood vessels are feeling in light of everything that is flowing by. You can measure everything you can think of that is flowing by, such as LDL cholesterol, triglycerides, or stress hormones, or you can simply ask the blood vessels, in essence: 'Given everything that is floating by, how are you feeling today?' " " And the blood vessels in this study said, 'we feel better after we've been fed walnuts daily.' " The results showed no significant weight gain among subjects receiving walnut supplementation. “..our study suggests you can make room for a highly nutritious food in your diet, particularly if it tends to fill you up, as nuts do. " Almonds, too, appear to have their own unique benefits for diabetes, he added. " Omega-3 fatty acids that are mostly in walnuts are very good for nerve development and the brain, and also the heart, but some research suggests that almonds have specific sugar-control qualities. " American Academy of Pain Medicine (AAPM) 26th Annual Meeting: Poster abstract 212645. 22. %%Are Different Oral Antidiabetics Associated With Different Adverse Outcomes? 2/16/2010 Risk of Cardiovascular Disease and All-Cause Mortality Among Patients With T2DM Prescribed Oral Antidiabetes Drugs: BMJ. 2009; Summary study used UK Database to investigate the risk for incident myocardial infarction (MI), congestive heart failure (CHF), and all- cause mortality associated with prescription oral antidiabetic agents. [5 million people].. The higher mortality risk associated with sulfonynureas (SUs) reported in the current study further suggests that SU therapy should perhaps be used sparingly, as suggested by recent guidelines. 23. %%MW Depression Linked to Increased Risk of Diabetes Mellitus in Older Individuals 2/18/10 Nonsevere, persistent, and untreated depression may lead to the development of diabetes in people older than 55 years. In addition, clinically significant depression was linked to a 65% increased risk of incident diabetes mellitus, writes the team The aim of the study was to examine the association between clinically significant depression (not limited to major depression disorder - MDD) and risk of diabetes development. The investigators also examined DM risk with respect to nonsevere depression, first- -ever depression, persistent depression, and untreated depression. [3521 subjects + 55 yrs] Results showed that " the risk of incident DM was higher among those with depression when compared with nondepressed subjects, The incidence rate was 19.70 per 1000 person-years for the depressed patients compared with 12.36 per 1000 person-years for the nondepressed patients. " the estimated rate of diabetes mellitus attributable to depression was 6.87%. " 24.%% JH Is Diabetes in Your Genes? In the US, nearly 10% of adults age 20 and older have diabetes. If you’re in this huge group, you may wonder if you inherited your DM. Scientists are still sorting out how heredity influences the risk of diabetes, but there is no doubt that the genes we receive from our parents play a vital role. It's important to keep in mind, though, that inheriting a given gene or set of genes does not guarantee you will develop DM. Instead, certain genes increase the susceptibility for developing the disease. Environment -- your eating habits, activity levels, stress, etc. -- also plays a significant role. Genes are units of biochemical information found in the nucleus of every cell that dictate how the body appears and functions. ... " variations " in certain genes seem to increase the risk of many diseases, including both major forms of diabetes. For instance, studies show that people with T1DM tend to have variations in genes that carry the code for producing immune system proteins. Variations in a number of genes appear to increase the risk of T2DM. However, genes alone do not cause DM in most cases. Something in the environment must " trigger " onset of the disease in people whose genes make them susceptible. While several theories attempt to explain what triggers T1, most evidence suggests that a high-fat Western diet and lack of exercise interacts with a person's genes to cause T2. 25.%% Oph 117,3 Mar 2010 OphSource In Vivo Retinal Morphology after Grid Laser Treatment in Diabetic Macular Edema Conclusions - Spectral domain OCT provides new insight into the immediate morphologic changes after laser treatment using the PASCAL laser system. Standardized grid photocoagulation induces characteristic homogenous alteration in the neurosensoric retinal layers. Biometric changes, indicating an immediate effect, were observed within 1 day after treatment. 26.%% Oph 117,3 Mar 2010 High-Resolution Imaging of the Human Retina In Vivo after Scatter Photocoagulation Treatment Using a Semiautomated Laser System Results - At day 1 after PRP, the photocoagulation effects were sharply delineated from the surrounding unaffected retina and all spots seemed to be identical in size and location. The area of tissue destruction was confined to the outer retinal layers, extending from the outer nuclear layer (ONL) to the retinal pigment epithelium (RPE). At 1 week, images showed a progressive loss of the affected outer retinal layers,..The ONL recovered partially, but the PRL inner and outer segments remained absent. During the long-term follow-up, RPE cells migrated to the center of the lesion, forming a hyperplastic scar. Conclusions - The characteristic morphology of retinal photocoagulation effects in vivo and over time was identified for the first time in human eyes using SD-OCT. 27.%% MNTD VEGF Trap-Eye Shows Positive Results In A Phase 2 Study In Patients With Diabetic Macular Edema 2/19/10 " The magnitude of the gain in visual acuity achieved with VEGF Trap-Eye in this Phase 2 study demonstrates the biologic activity of VEGF Trap-Eye in treating diabetic macular edema, a disease in which high levels of vascular endothelial growth factor (VEGF) are present, " said the Principal Investigator for the study.The adverse events reported were those typically associated with intravitreal injections or the underlying disease. Including: conjunctival hemorrhage, eye pain, floaters (myodesopsia), ocular redness (hyperemia), and increased intraocular pressure. 28.%% MedWatch - The FDA Safety Info.. Adverse Event Reporting Program OneTouch SureStep Test Strips (LifeScan): Recall LifeScan and FDA notified healthcare professionals of a voluntary recall of eight lots of OneTouch SureStep Test Strips which are being recalled because they may provide falsely low glucose results when the glucose level is higher than 400 mg/dL. If patients use the falsely low test results to determine their insulin dose, they may give themselves too little insulin, which could result in poor blood glucose control. The 8 lots of Test Strips being recalled are identified in the firm's press release. Lot numbers are located on the outer carton and test strip vial. LifeScan estimates approximately fourteen thousand packages were distributed nationwide between August 1, 2009 and January 28, 2010. It is important that patients with recalled test strips continue to test their blood glucose. Patients with access to a meter that does not use OneTouch SureStep Test Strips should use this other meter to test their blood glucose until replacement product from LifeScan arrives. If an alternate meter is not available, patients may continue to test using the recalled OneTouch SureStep Test Strips. However, if patients obtain results above 400 mg/dL, they should contact their healthcare professional for further instructions because their glucose may be significantly higher. Read the complete MedWatch 2010 Safety summary & link to the firm's press release, at: www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalPro ducts/ucm202254.htm - Abbreviations: DM - diabetes Mellitus;T1DM - type 1 diabetes mellitus T2DM - type 2; DME - diabetic macular edema; GDM - gestational diabetes; FPG - fasting plasma glucose BP - blood pressure; CVD - cardio-vascular disease; MI -myocardial infarction or heart attack ;HTN - hypertension or high BP; OCT - optical coherence tomography; VA - visual acuity -ADA - Amer Diabetes Ass & ADA Professional Resource Online; FDA Federal Drug Adm. JHA - s Hopkins Alerts ; MW Medscape Web MD; NIH - National Institutes of Health; MNTD- Medical News Today Definitions via online Medical dictionaries. Disclaimer, I am a BSN RN but not a diabetic or diabetic educator. Reports are excerpted unless otherwise noted. This project is done as a courtesy to the blind/visually impaired and diabetic communities. Dawn Wilcox BSN RN Coordinator The Health Library at Vista Center; an affiliate of the Stanford Hospital Health Library. contact above e-mail or thl@... Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.